Cipla to acquire generic businesses in US for $550m

The combined revenue from these transactions is over $200 million for the year ended December 2014 and over $225 million in the 12 months to June 2015, Cipla said in a statement. Photo: Mint

Mumbai-based Cipla Ltd on Friday announced that its UK arm Cipla EU will acquire two US-based companies, InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc., for $550 million.

The combined revenue from these transactions is over $200 million for the year ended December 2014 and over $225 million in the 12 months to June 2015, Cipla said in a statement.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter